Check-Cap (NASDAQ:CHEK) Stock Rating Upgraded by Wall Street Zen

Check-Cap (NASDAQ:CHEK) was upgraded by analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Check-Cap Price Performance

CHEK stock opened at $1.98 on Friday. The company has a market capitalization of $11.56 million, a P/E ratio of -0.71 and a beta of 0.41. Check-Cap has a 12 month low of $0.56 and a 12 month high of $3.13. The firm’s fifty day simple moving average is $1.77 and its 200-day simple moving average is $1.12.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.